Xpert MTB/RIF for rapid detection of rifampicin-resistant Mycobacterium tuberculosis from pulmonary tuberculosis patients in Southwest Ethiopia

Abstract

Xpert MTB/RIF was highly effective at identifying RIF-resistant strains in smear- or culture-positive samples. RIF resistance based on Xpert MTB/RIF results could be used to estimate MDR and allow rapid initiation of MDR-TB treatment in regions with high levels of drug-resistant TB.

Prevalence of rifampicin resistant pulmonary tuberculosis using geneXpert assay in Ethiopia, a systematic review and meta-analysis

“…The remaining 63 articles were subjected to full-text screening. Finally, 34 articles fulfilled the eligibility criteria and were enrolled in the meta-analysis [ [13] , [14] , [15] , [16] , [17] , [18] , [19] , [20] , [21] , [22] , [23] , [24] , [25] , [26] , [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] , [35] , [36] , [37] , [38] , [39] , [40] , [41] , [42] , [43] , [44] , [45] , [46] ]. The article selection was carried out following the PRISMA flow diagram ( Fig.…”

“…The prevalence of rifampicin resistant PTB among the included studies in Ethiopia varied from 2.3% to 34.3% across studies in the country [ [13] , [14] , [15] , [16] , [17] , [18] , [19] , [20] , [21] , [22] , [23] , [24] , [25] , [26] , [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] , [35] , [36] , [37] , [38] , [39] , [40] , [41] , [42] , [43] , [44] , [45] , [46] ]. The pooled prevalence of rifampicin resistance among regions ranged from 8.5% to 11.8%.…”

Diagnosing Drug-Resistant Tuberculosis with the Xpert<sup>®</sup>MTB/RIF. The Risk for Rifampin Susceptible Cases

“…This problems will be worse in settings with high prevalence of poly-drug resistance (isoniazid resistance associated with resistance to pyrazinamide or ethambutol, or both), which can cause even higher rates of failure and relapse [15]. This is not a local or regional problem, since resistance to isoniazid without resistance to rifampin has been reported worldwide, especially in regions with high burden of drug resistant TB [16]. It is urgent that national TB programs implement the necessary infrastructure to complement the Xpert®MTB/RIF results with DST either by phenotypic or genotypic methods.…”

Limitations of the Xpert-MTB/RIF® assay in the initial diagnosis of tuberculosis in the context of a rural hospital in Ethiopia

“…En Etiopía se puso en marcha en determinados laboratorios por todo el país, a partir de 2012 [ 4 ]. Numerosos estudios demuestran las ventajas diagnósticas que aporta Xpert MTB/RIF® [ 3 , 5 , 6 ], al facilitar que más pacientes comiencen un tratamiento adecuado lo antes posible.…”